ArticleSensors (Basel, Switzerland)2022
To Assist Oncologists: An Efficient Machine Learning-Based Approach for Anti-Cancer Peptides Classification.
Article in Sensors (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 26 citations in OpenAlex.
- Reliable ECG classification using parallel hybrid models with limited resources.Scientific reports · 2026Article
- Deep capsule neural network for identifying anticancer peptides using sequence to image transformation-based local embedded features.BMC biology · 2026Article
- Artificial intelligence-driven anticancer peptide discovery.iMetaOmics · 2025Review
- Explainable AI-driven prediction of APE1 inhibitors: enhancing cancer therapy with machine learning models and feature importance analysis.Molecular diversity · 2025Article
- Extended dipeptide composition framework for accurate identification of anticancer peptides.Scientific reports · 2024Article
- Article
- An efficient consolidation of word embedding and deep learning techniques for classifying anticancer peptides: FastText+BiLSTM.PeerJ. Computer science · 2024Article
- ACPPfel: Explainable deep ensemble learning for anticancer peptides prediction based on feature optimization.Frontiers in genetics · 2024Article
- Improving the Efficiency of Multistep Short-Term Electricity Load Forecasting via R-CNN with ML-LSTM.Sensors (Basel, Switzerland) · 2022Article
- A novel deep learning-assisted hybrid network for plasmodium falciparum parasite mitochondrial proteins classification.PloS one · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In the modern technological era, Anti-cancer peptides (ACPs) have been considered a promising cancer treatment. It's critical to find new ACPs to ensure a better knowledge of their functioning processes and vaccine development. Thus, timely and efficient ACPs using a computational technique are highly needed because of the enormous peptide sequences generated in the post-genomic era. Recently, numerous adaptive statistical algorithms have been developed for separating ACPs and NACPs. Despite great advancements, existing approaches still have insufficient feature descriptors and learning methods, limiting predictive performance. To address this, a trustworthy framework is developed for the precise identification of ACPs. Particularly, the presented approach incorporates four hypothetical feature encoding mechanisms namely: amino acid, dipeptide, tripeptide, and an improved version of pseudo amino acid composition are applied to indicate the motif of the target class. Moreover, principal component analysis (PCA) is employed for feature pruning, while selecting optimal, deep, and highly variated features. Due to the diverse nature of learning, experiments are performed over numerous algorithms to select the optimum operating method. After investigating the empirical outcomes, the support vector machine with hybrid feature space shows better performance. The proposed framework achieved an accuracy of 97.09% and 98.25% over the benchmark and independent datasets, respectively. The comparative analysis demonstrates that our proposed model outperforms as compared to the existing methods and is beneficial in drug development, and oncology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.